On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community ...

Meta: In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...